Retatrutide

Half-life context

Unknown. No verified formulation-specific human estimate in this source set; no guessed value is supplied.

Regulatory status

Checked 2026-10-09

FDA product approval

not approved. FDA identifies this investigational substance as unapproved.

Compounding

restricted. FDA states this substance cannot be used in compounding under federal law.

Research status

investigational. Human obesity trials; trial findings do not authorize unsupervised use.

Sport status

unknown. Not individually verified; consult the current sport rules. Absence of a listing is not permission.

Evidence B

Randomized human investigational evidence; applicability is limited to the studied population.

Grades describe the cited population and indication, not safety or suitability for an individual.

Population: Human obesity trials; trial findings do not authorize unsupervised use.

Indication: No general wellness indication established.

Basis: Randomized human phase 2 trials provide indication-specific evidence; investigational status does not establish approval or general safety.

Risks

• Safety is incomplete; absence of reports does not establish safety.

Contraindications

• Unknown or incomplete for research formulations; this is not a clearance for use.

Interactions

• Unknown or incomplete; do not infer compatibility with medications or other substances.

What to record

• Existing clinician-directed records, symptoms and dated health measurements.
• Record missing data; trends do not demonstrate causation.

A licensed clinician must interpret the evidence for your situation. This entry provides education, not treatment instructions.

Review: source-curated; clinician review pending

Sources

• Primary evidence or regulator source. Checked 2026-10-09
• FDA unapproved GLP-1 safety statement. Checked 2026-10-09